JP2011515472A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515472A5
JP2011515472A5 JP2011501846A JP2011501846A JP2011515472A5 JP 2011515472 A5 JP2011515472 A5 JP 2011515472A5 JP 2011501846 A JP2011501846 A JP 2011501846A JP 2011501846 A JP2011501846 A JP 2011501846A JP 2011515472 A5 JP2011515472 A5 JP 2011515472A5
Authority
JP
Japan
Prior art keywords
patent document
bendamustine hydrochloride
ribosepharm
discloses
bendamustine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011501846A
Other languages
English (en)
Japanese (ja)
Other versions
JP5536753B2 (ja
JP2011515472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/001956 external-priority patent/WO2009120386A2/en
Publication of JP2011515472A publication Critical patent/JP2011515472A/ja
Publication of JP2011515472A5 publication Critical patent/JP2011515472A5/ja
Application granted granted Critical
Publication of JP5536753B2 publication Critical patent/JP5536753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011501846A 2008-03-26 2009-03-26 ベンダムスチン塩酸塩の新規固体形態 Active JP5536753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3975208P 2008-03-26 2008-03-26
US61/039,752 2008-03-26
PCT/US2009/001956 WO2009120386A2 (en) 2008-03-26 2009-03-26 Novel solid forms of bendamustine hydrochloride

Publications (3)

Publication Number Publication Date
JP2011515472A JP2011515472A (ja) 2011-05-19
JP2011515472A5 true JP2011515472A5 (enExample) 2013-05-23
JP5536753B2 JP5536753B2 (ja) 2014-07-02

Family

ID=41051023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501846A Active JP5536753B2 (ja) 2008-03-26 2009-03-26 ベンダムスチン塩酸塩の新規固体形態

Country Status (12)

Country Link
US (9) US20090264488A1 (enExample)
EP (2) EP3150197A1 (enExample)
JP (1) JP5536753B2 (enExample)
CN (3) CN103550159B (enExample)
AR (1) AR072777A1 (enExample)
CA (1) CA2718939A1 (enExample)
CL (1) CL2009000742A1 (enExample)
ES (1) ES2605205T3 (enExample)
HK (1) HK1220966A1 (enExample)
MX (2) MX2010010398A (enExample)
TW (1) TWI472515B (enExample)
WO (1) WO2009120386A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JP5406197B2 (ja) * 2007-10-09 2014-02-05 ユーエス ワールドメッズ リミテッド ライアビリティ カンパニー ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) * 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010144675A1 (en) * 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
EP2516404A4 (en) 2009-12-23 2013-04-17 Reddys Lab Ltd Dr PREPARATION OF BENDAMUSTINE AND ITS SALTS
HUE054836T2 (hu) 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
JP6209446B2 (ja) 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
CN101948437B (zh) * 2010-06-28 2012-08-29 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀的精制方法
WO2012059935A1 (en) 2010-11-01 2012-05-10 Shilpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
WO2012103226A2 (en) * 2011-01-25 2012-08-02 Dr. Reddy's Laboratories Ltd. Bendamustine formulations
WO2012106117A1 (en) * 2011-01-31 2012-08-09 Cephalon, Inc. Methods for the preparation of bendamustine
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
CN102351799B (zh) * 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀晶型及其制备方法
EP2617716A1 (en) 2012-01-18 2013-07-24 Arevipharma GmbH Process for the preparation of bendamustine hydrochloride and related compounds
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
WO2013150020A1 (en) 2012-04-03 2013-10-10 Synthon Bv Process for making bendamustine
EP2656843B1 (en) 2012-04-26 2015-03-18 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2958554B1 (en) 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
US9315469B2 (en) 2013-03-14 2016-04-19 Johnson Matthey Public Limited Company Process for drying bendamustine hydrochloride monohydrate
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
WO2015138199A1 (en) 2014-03-13 2015-09-17 Voudouris Vasilios Bendamustine solid dispersions and continuous infusion
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
BR112017026586B1 (pt) * 2015-06-09 2021-11-03 Rebiotix, Inc. Composições de terapia de restauração de microbiota (mrt) e métodos de fabricação
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
AU2018346395A1 (en) 2017-10-05 2020-04-30 Mecox Curemed Co., Ltd. Oral bendamustine formulations
CN111093654B (zh) * 2017-11-07 2023-03-10 江苏恒瑞医药股份有限公司 一种盐酸苯达莫司汀的晶体及其制备方法
EA037673B1 (ru) * 2018-07-04 2021-04-29 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина
CA3108321A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2023067188A1 (en) 2021-10-22 2023-04-27 Project Pharmaceutics Gmbh Liquid pharmaceutical formulation

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
DE159877C (enExample) *
DE293808C (enExample)
DE80967C (enExample)
DD80967A (enExample)
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
ATE65402T1 (de) 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
EP1005870B1 (en) * 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
NZ273752A (en) * 1993-10-27 1998-03-25 Upjohn Co Stabilised prostaglandin e1 lyophilisate using tertiary butanol and lactose carriers
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
JPH11511463A (ja) 1995-08-31 1999-10-05 スミスクライン・ビーチャム・コーポレイション インターロイキン変換酵素およびアポプトーシス
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CA2294247C (en) 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
PT1104297E (pt) * 1998-07-09 2006-05-31 Cephalon Inc Composicoes para o tratamento da leucemia linfocitica cronica
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
EP1350793A1 (en) * 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
PL362979A1 (en) * 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
WO2002080996A1 (de) * 2001-04-03 2002-10-17 Franz Herbst Medizinisches implantat und verfahren zu seiner herstellung
WO2003034944A1 (de) * 2001-10-15 2003-05-01 Hemoteq Gmbh Beschichtung von stents zur verhinderung von restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
CA2478111C (en) 2002-03-22 2012-10-02 Ludwig Maximilians Universitat A cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
US20050176678A1 (en) 2002-05-09 2005-08-11 Roland Horres Compounds and method for coating surfaces in a haemocompatibe manner
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
AU2003286796A1 (en) 2002-10-31 2004-06-07 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7157551B2 (en) * 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
CA2585659A1 (en) * 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
ES2350452T3 (es) 2004-11-22 2011-01-24 Venus Remedies Limited Formulación parenteral de aceclofenaco líquido no acuoso.
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
ES2365410T3 (es) 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ITUD20070130A1 (it) 2007-07-23 2009-01-24 C M E Spa Sa Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
EP2424506A1 (en) 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine

Similar Documents

Publication Publication Date Title
JP2011515472A5 (enExample)
JP2013537891A5 (enExample)
JP2008523153A5 (enExample)
UY32599A (es) Formulación oral sólida de abt-263
CN113412260A (zh) 己酮糖激酶抑制剂及其用途
JP2014513484A5 (enExample)
JP2013542247A5 (enExample)
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
JP2011116755A5 (enExample)
JP2014519662A5 (enExample)
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
MX378856B (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
FI3300743T3 (fi) Menetelmiä rokotteen antamiseksi
ES2409069R1 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
DE602007011384D1 (de) Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
Al-Karmalawy et al. Design and statistical optimisation of emulsomal nanoparticles for improved anti-SARS-CoV-2 activity of N-(5-nitrothiazol-2-yl)-carboxamido candidates: in vitro and in silico studies
WO2008070350A3 (en) Methods and compositions related to wrapping of dehydrons
JP2018529717A5 (enExample)
Taheri et al. Study the effects of metformin on renal function and structure after unilateral ischemia-reperfusion in rat
JP2012504616A5 (enExample)
TN2012000431A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
BR112012013199A2 (pt) composto, composição farmacêutica, e , uso de um composto
MX2011011526A (es) Formulacion lipida de promotor de apoptosis.
EP4167984A1 (en) Anti-viral compounds and methods of using same